UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of Earliest event Reported): March 4, 2008 (February 29, 2008) |
||||||||
| CHINA BIOLOGIC PRODUCTS, INC. | ||||||||
| (Exact name of registrant as specified in its charter) | ||||||||
| Delaware | 000-52807 | 75-2308816 | ||||||
| (State or other jurisdiction of | (Commission File Number.) | (IRS Employer Identification No.) | ||||||
| incorporation or organization) | ||||||||
| No. 14 East Hushan Road, | ||||||||
| Taian City, Shandong 271000 | ||||||||
| People’s Republic of China | ||||||||
| (Address of Principal Executive Offices) | ||||||||
| (+86) 538 -620-3897 | ||||||||
| Registrant’s Telephone Number, Including Area Code | ||||||||
| N/A | ||||||||
| (Former name or former address, if changed since last report) | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS On February 29, 2008, the common stock of China Biologic
Products, Inc. (the "Company") was approved for quotation on the
Over-the-Counter Bulletin Board maintained by the Financial Industry Regulatory
Authority (FINRA). The Company’s common stock will be quoted on the
Over-the-Counter Bulletin Board under the new symbol CBPO.OB. A copy of the
Company’s press release announcing the event is attached hereto as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits
| Number | Description |
| 99.1 | Press Release |
SIGNATURES Pursuant to the requirements of the
Securities and Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
| CHINA BIOLOGIC PRODUCTS, INC. | ||
| Date: March 4, 2008 | /s/ Stanley Wong | |
| Stanley Wong | ||
| President and Chief Executive Officer | ||
Exhibit Index
| Number | Description |
| 99.1 | Press Release |